publication date: Jan. 25, 2017

NCI CTEP-Approved Trials for January

The NCI Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.


Phase I 9979

Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases

Mayo Clinic Cancer Center LAO

Mohindra, Pranshu

(410) 328-6080


Phase II 9984

A Randomized Phase 2 Study of Cediranib in Combination with Olaparib Versus Olaparib Alone in Men with Metastatic Castration Resistant Prostate Cancer

Yale University Cancer Center LAO

Kim, Joseph Woong

(203) 737-1600


Phase II ANHL1522

A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)

Children’s Oncology Group Wistinghausen, Birte

(212) 241-7022


Phase II EA2161

A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET) ECOG-ACRIN Cancer Research Group

Rajdev, Lakshmi

(718) 405-8404


Phase II/III 

NRG-GU002 Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel 

NRG Oncology

Hurwitz, Mark David

(212) 955-6644

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.